高流量鼻导管通气与持续气道正压通气及经鼻间歇正压通气作为胎龄≥32周婴儿主要呼吸支持的三臂多中心随机对照试验研究方案
本研究为评估者盲法、三臂、多中心、平行随机对照试验,纳入胎龄≥32周、生后24小时内需无创通气的呼吸窘迫新生儿,随机分至高流量鼻导管通气组、持续气道正压通气组或经鼻间歇正压通气组,比较三种无创通气模式作为主要呼吸支持的有效性、安全性和舒适度。主要结局为入组后72小时内治疗失败的发生率。
要点
- 胎龄≥32周新生儿呼吸窘迫的无创通气模式选择证据有限,尤其经鼻间歇正压通气。
- 主要结局为入组后72小时内治疗失败发生率,同时评估安全性、舒适度及多项次要结局。
- 研究旨在为胎龄≥32周呼吸窘迫新生儿制定呼吸治疗策略提供临床证据。
核心结论
- 目前关于胎龄≥32周新生儿使用经鼻间歇正压通气的数据匮乏,本研究将为该人群呼吸窘迫的呼吸治疗策略提供临床证据,以减少气管插管发生率并降低无创通气相关并发症。
研究设计与样本
- 评估者盲法、三臂、多中心、平行随机对照试验,纳入胎龄≥32周、生后24小时内需主要无创通气的呼吸窘迫新生儿,随机分为高流量鼻导管通气组、持续气道正压通气组和经鼻间歇正压通气组。
主要发现
- 主要结局为入组后72小时内治疗失败的发生率。
- 次要结局包括出院前死亡、随机化后72小时内表面活性物质治疗、无创和有创机械通气时长、氧疗时长、支气管肺发育不良、达到全肠内营养时间、坏死性小肠结肠炎、住院时长、住院费用、漏气综合征、鼻部创伤和舒适度评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health problems in neonates with gestational age (GA) ≥ 32 weeks remain a major medical concern. Respiratory distress (RD) is one of the common reasons for admission of neonates with GA ≥ 32 weeks. Noninvasive ventilation (NIV) represents a crucial approach to treat RD, and currently, the most used NIV modes in neonatal intensive care unit include high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), and nasal intermittent positive pressure ventilation. Although extensive evidence supports the use of NIPPV in neonates with a GA < 32 weeks, limited data exist regarding its effectiveness in neonates with GA ≥ 32 weeks. Therefore, the aim of this study is to compare the clinical efficacy of HFNC, CPAP, and NIPPV as primary NIV in neonates with GA ≥ 32 weeks who experience RD. METHODS: This trial is designed as an assessor-blinded, three-arm, multi-center, parallel, randomized controlled trial, conducted in neonates ≥ 32 weeks' GA requiring primary NIV in the first 24 h of life. The neonates will be randomly assigned to one of three groups: HFNC, CPAP or NIPPV group. The effectiveness, safety and comfort of NIV will be evaluated. The primary outcome is the occurrence of treatment failure within 72 h after enrollment. Secondary outcomes include death before discharge, surfactant treatment within 72 h after randomization, duration of both noninvasive and invasive mechanical ventilation, duration of oxygen therapy, bronchopulmonary dysplasia, time to achieve full enteral nutrition, necrotizing enterocolitis, duration of admission, cost of admission, air leak syndrome, nasal trauma, and comfort score. DISCUSSION: Currently, there is a paucity of data regarding the utilization of NIPPV in neonates with GA ≥ 32 weeks. This study will provide clinical evidence for the development of respiratory treatment strategies in neonates at GA ≥ 32 weeks with RD, with the aim of minimizing the incidence of tracheal intubation and reducing the complications associated with NIV. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2300069192. Registered on March 9, 2023, https://www.chictr.org.cn/showproj.html?proj=171491 .
引用
- Zhou R, Xiong T, Tang J, et al. High-flow nasal cannula (HFNC) vs continuous positive airway pressure (CPAP) vs nasal intermittent positive pressure ventilation as primary respiratory support in infants of ≥ 32 weeks gestational age (GA): study protocol for a three-arm multi-center randomized controlled trial. Trials. 2023. PMID: 37803402. doi:10.1186/s13063-023-07665-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。